Why UBS thinks this is the time to buy CSL Limited (ASX:CSL) shares

The sell-off in this market darling may be over with CSL Limited's (ASX: CSL) share price enjoying its second consecutive day of gains as UBS upgrades the stock.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The sell-off of this market darling may be over with CSL Limited's (ASX: CSL) share price enjoying its second consecutive day of gains as UBS upgrades the stock to "buy" from "neutral".

The stock is outperforming the flat S&P/ASX 200 (Index:^AXJO) (ASX: XJO) index this morning as it is rallying 0.9% higher to $192.67 but is still down 16% from its September peak.

It's not the only healthcare stock that's running ahead at the time of writing though. The Cochlear Limited (ASX: COH) share price and RESMED/IDR UNRESTR (ASX: RMD) share price are also making big gains, although CSL is the only one in the sector scoring an upgrade from UBS.

Why the upgrade?

The broker made the recommendation upgrade after reviewing the latest results from CSL's competitors Shire and Grifols Bioscience.

It believes that CSL's immunoglobulin (IG) portfolio continues to grow faster than the rest of the market and that the company can generate a compound annual growth rate (CAGR) of around 11% over the next three years.

That means its forecast price-earnings (P/E) multiple of around 30 times isn't unwarranted even though that's nearly double the P/E of the S&P/ASX 200.

However, the broker has lowered its earnings per share (EPS) forecast on the stock by around 6% due in part to changes in its exchange rate assumptions, and that has resulted in a drop in its price target for CSL to $220 from $232 per share.

That still leaves plenty of upside for the stock, which had crashed to a six-month low of $174.69 just two weeks ago as high P/E stocks took the brunt of the October market sell-off.

"CSL is trading on a 12-mth forward PE of 30.2x, a 97% premium to the ASX200, compared to 2-year averages of 29.7x and 87% respectively," said UBS.

"On a PE vs 2-year forward EPS growth basis, it screens favourably relative to a basket of listed Australian healthcare companies. Our DCF-based valuation of A$220 is arguably a better reflection of inherent value noting sustained EPS growth forecasts over the longer term."

There's plenty to like about CSL given its strong track record in generating shareholder returns. I rate this as one of the most admired stocks on the market along with Macquarie Group Ltd (ASX: MQG).

Foolish Takeaway

While I think CSL has probably seen the bottom in this cycle, I am more inclined to buy value stocks in anticipation of the next market upswing as we approach the end of the calendar year.

Looking for other blue-chip stock ideas as we head into the "Santa Rally" season? The experts at the Motley Fool have picked their best blue-chip stock ideas and you can find out what these are for free by following the link below.

Motley Fool contributor Brendon Lau owns shares of Macquarie Group Limited. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to a disappointing week for investors this Friday.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Betr, Centuria Capital, GR Engineering, and Mach7 shares are pushing higher

These shares are having a good finish to the week. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX gave up an afternoon lead to close lower today.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Clarity Pharmaceuticals, Kelsian, Life360, and Syrah shares are rising today

These shares are pushing higher on Thursday. But why?

Read more »

Man smiling on top of rocks with mountains in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were in a nervous mood today.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Why Beach Energy, Boss Energy, Cochlear, and Light & Wonder shares are pushing higher

These shares are having a good time on hump day. But why?

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing Tuesday session for ASX investors today.

Read more »

A man looking at his laptop and thinking.
Share Gainers

Thinking of selling your CBA shares? This expert says you should hold on

CBA shares are up by about 80% since November 2023.

Read more »